NorthStrive Biosciences Advances AI-Driven Drug Discovery to Phase III for Muscle Preservation in Obesity Treatment
核心洞察
NorthStrive Biosciences (搜索) has initiated Phase III of its AI Development Program with Yuva Biosciences (搜索) to experimentally validate small-molecule candidates targeting muscle preservation through mitochondrial function improvements.
The program utilizes YuvaBio's proprietary MitoNova™ AI platform to identify compounds that may upregulate ANT1 (搜索), a key gene involved in metabolic function and muscle integrity.
Phase III will focus on addressing muscle preservation concerns in obesity treatment, particularly for patients using GLP-1 receptor agonists, with experimental validation expected to take 6 to 9 weeks.
NorthStrive Biosciences (搜索) Inc., a subsidiary of PMGC Holdings (搜索) Inc. (NASDAQ:ELAB), announced the initiation of Phase III of its AI Development Program with Yuva Biosciences (搜索), Inc. (YuvaBio) on December 17, 2025. This phase represents a significant advancement from computational screening to experimental validation of AI-identified compounds targeting muscle preservation in obesity treatment.
AI-Driven Compound Identification Moves to Experimental Validation
Phase III builds on the results of Phase II, where YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, MitoNova™, identified a shortlist of small-molecule candidates through computational screening. These candidates demonstrate potential to promote mitochondrial health and support muscle preservation, addressing a growing concern in obesity treatment, particularly for patients using GLP-1 receptor agonists.
The experimental validation phase will generate meaningful biological data on potential drug compounds prioritized by YuvaBio's classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function. YuvaBio will begin generating biological data on these AI-selected compounds, including cytotoxicity screening and ANT1 (搜索) expression testing at multiple timepoints.
Targeting ANT1 for Metabolic Function
The experimental work is specifically designed to identify candidates that may upregulate ANT1 (搜索), a key gene involved in metabolic function and muscle integrity. Using an exclusive dataset on mitochondrial biogenesis, the AI prioritization focuses experimental testing on the most promising candidates, reducing the number of compounds advanced for subsequent development.
Phase III is expected to accelerate discovery on small-molecule candidates which may promote mitochondrial health and support muscle preservation. The phase is anticipated to take approximately 6 to 9 weeks to complete.
Strategic Partnership and Technology Platform
Yuva Biosciences (搜索) leverages mitochondrial science and advanced artificial intelligence to identify and develop therapeutic candidates targeting aging-related and metabolic pathways. The company's proprietary AI platform, MitoNova™, integrates biological, chemical, and mitochondrial-function datasets to accelerate the discovery of compounds with potential to improve cellular energy, metabolic health, and tissue function.
NorthStrive Biosciences (搜索) focuses on the development and acquisition of cutting-edge aesthetic medicines, with its lead asset, EL-22, leveraging an engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
Addressing Unmet Medical Need
The advancement to Phase III marks a significant step towards advancing NorthStrive Biosciences (搜索)' pipeline of therapies addressing obesity and related metabolic conditions. The focus on muscle preservation represents a critical unmet need in current obesity treatments, where muscle loss can be a significant concern for patients undergoing weight loss therapies.